Absence of an association between G-CSF support and clinical response in heavily pre-treated ovarian cancer patients receiving salvage chemotherapy with paclitaxel (Taxol).
This study was undertaken to determine if there was an association between the use of granulocyte colony-stimulating factor (G-CSF) and the clinical response to paclitaxel in patients with advanced ovarian cancer. Seventy-seven heavily pre-treated patients were given 135 mg/m2 paclitaxel every 21 days, with G-CSF support as necessary according to standard criteria. Patients were stratified into two subgroups according to the presence or absence of G-CSF use. The clinical response, progression-free interval (PFI) and survival were determined for each patient and analyzed relative to G-CSF use. Thirty-three patients received G-CSF support. The overall response rate was 32% (one complete and 24 partial) with similar patient numbers from each subgroup. The mean PFI and survival were not significantly different between the subgroups; 170.9 +/- 21.2 and 401 +/- 45.5 days (G-CSF) and 182.4 +/- 30.2 and 367 +/- 36 days (no G-CSF), respectively. We conclude that G-CSF use is not associated with response to paclitaxel in heavily pre-treated ovarian cancer patients.
Johnston
C M
CM
Department of Obstetrics and Gynecology, University of Michigan Medical Center, Ann Arbor, USA.
Pearl
L
L
D000328:Adult; D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D007213:Indomethacin; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality; D017239:Paclitaxel / Q000627:therapeutic use*; D016879:Salvage Therapy; D015996:Survival Rate
D000972:Antineoplastic Agents, Phytogenic; D016179:Granulocyte Colony-Stimulating Factor; D017239:Paclitaxel; D007213:Indomethacin